The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 22nd 2024
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
Dr. Weber on FDA Approval of Pembrolizumab for Stage III Melanoma
February 19th 2019Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone's Perlmutter Cancer Center, a 2016 Giant of Cancer Care in Melanoma, discusses the FDA approval of pembrolizumab for stage III melanoma.
Dr. Triebel on the Rationale for a Novel Immunotherapy Combination in Melanoma
January 30th 2019Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immutep Ltd, discusses the rationale for a novel immunotherapy combination in patients with unresectable or metastatic melanoma.
Dr. Ribas on Combination Immunotherapy and Radiation in Melanoma
January 22nd 2019Antoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses the potential for combination immunotherapy and radiation in the treatment of patients with melanoma.
Pembrolizumab Granted 5 Additional Approvals in Japan
January 3rd 2019The Japan Pharmaceuticals and Medical Devices Agency has approved pembrolizumab for 5 new indications, including melanoma, advanced microsatellite instability-high tumors, and 3 expanded uses in advanced non–small cell lung cancer.
Dr. Hamid on the FDA Approval of Pembrolizumab in Merkel Cell Carcinoma
December 20th 2018Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Cemiplimab Antitumor Activity in CSCC Sustained With Longer Follow-up
The monoclonal anti-PD-1 antibody cemiplimab continued to demonstrate considerable antitumor activity and durable responses in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma.
Avelumab Continues to Show Value in JAVELIN Merkel 200 Analyses
December 1st 2018In an analysis of patient-reported outcomes of the JAVELIN Merkel 200 trial of avelumab (Bavencio), investigators found that there was a similarity in proportion of responders with metastatic Merkel cell carcinoma based on clinical and patient-reported outcome endpoints.
Triplet Therapy With Novel PD-1 Inhibitor Holds Promise in Melanoma
The addition of a novel PD-1 inhibitor to a combination of BRAF inhibitor dabrafenib (Tafinlar) and MEK inhibitor trametinib (Mekinist) is being tested to determine whether the triplet is safe and effective for patients with metastatic or unresectable melanoma.
Dr. Weber on Duration of Checkpoint Inhibitor Therapy in Melanoma
November 15th 2018Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses duration of checkpoint inhibitor therapy in patients with melanoma.
Dr. Ascierto on Choosing Combinations in Treatment of Melanoma
October 24th 2018Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses how to choose between combination therapies in the treatment of patients with melanoma.
Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma
Long-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treated with adjuvant dabrafenib plus trametinib.
Dr. Flaherty Discusses BRAF Inhibitors in Melanoma
October 11th 2018Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses BRAF inhibitors for the treatment of patients with melanoma.
Dr. Postow on FDA Approval of Cemiplimab in Metastatic Cutaneous Squamous Cell Carcinoma
September 29th 2018Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of cemiplimab in patients with advanced or metastatic cutaneous squamous cell carcinoma.
Dr. Rischin on the FDA Approval of Cemiplimab for CSCC
September 29th 2018Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the FDA approval of cemiplimab for the treatment of patients with cutaneous squamous cell carcinoma.